S100A9 and Sepsis: Tasquinimod and Paquinimod are currently commonly used pharmacological inhibitors of S100A9, and it has been found that inhibiting S100A9 with Paquinimod can reduce sepsis induced mitochondrial dysfunction, oxidative stress, and immunosuppression through multiple pathways [33, 34].